Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Maintains Buy on Verona Pharma, Raises Price Target to $26

BTIG analyst Thomas Shrader maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $17 to $26.
byBenzinga Newsdesk
December 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

BTIG analyst Thomas Shrader maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $17 to $26.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0